HC Wainwright Reiterates Buy Rating for Janux Therapeutics (NASDAQ:JANX)

HC Wainwright reissued their buy rating on shares of Janux Therapeutics (NASDAQ:JANX - Free Report) in a research note released on Monday morning,Benzinga reports. They currently have a $70.00 target price on the stock. HC Wainwright also issued estimates for Janux Therapeutics' Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $2.82 EPS.

JANX has been the subject of a number of other research reports. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Cantor Fitzgerald restated an "overweight" rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Wedbush reissued an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Leerink Partnrs upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Janux Therapeutics has a consensus rating of "Buy" and a consensus price target of $88.00.

Remove Ads

Janux Therapeutics Stock Down 2.4 %

JANX traded down $0.75 during trading on Monday, hitting $30.75. The company had a trading volume of 1,026,971 shares, compared to its average volume of 814,574. The company has a market capitalization of $1.61 billion, a PE ratio of -26.28 and a beta of 3.16. Janux Therapeutics has a one year low of $29.63 and a one year high of $71.71. The firm's 50-day moving average price is $42.23 and its 200 day moving average price is $47.67.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the sale, the chief executive officer now owns 217,054 shares in the company, valued at $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,002 shares of company stock worth $2,684,703. 29.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JANX. Plato Investment Management Ltd boosted its position in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after acquiring an additional 187 shares during the period. Russell Investments Group Ltd. grew its position in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $59,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after buying an additional 339 shares in the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Janux Therapeutics in the fourth quarter valued at approximately $139,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.